Effect of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging
Public ClinicalTrials.gov record NCT01221272. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Cross-over Trial to Evaluate the Effects of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study enrolled participants with documented exercise-induced myocardial ischemia in order to evaluate whether ranolazine, when taken prior to exercise, can improve blood flow to the heart (myocardial perfusion), as assessed by exercise-induced myocardial perfusion defect size (PDS) and total perfusion deficit (TPD), using gated single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI). This was a 2-period crossover study. The last dose of each period must have been taken 3-4 hours prior to conduct of the exercise SPECT MPI. After the research exercise SPECT MPI was performed at the end of Period 1, participants discontinued the treatment they were randomized to for that period and began the other treatment in Period 2.
Study identification
- NCT ID
- NCT01221272
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 81 participants
Conditions and interventions
Conditions
Interventions
- Ranolazine Drug
- Placebo to match ranolazine Drug
- SPECT MPI Procedure
- Exercise Behavioral
Drug · Procedure · Behavioral
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2010 (Type not available)
- Primary completion
- Sep 2012 (Actual)
- Completion
- Sep 2012 (Actual)
- Last update posted
- Sep 3, 2014
2010 – 2012
United States locations
- U.S. sites
- 26
- U.S. states
- 16
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | — |
| Imperial Cardiac Center | Imperial | California | 92251 | — |
| Clinical Trials Research | Lincoln | California | 95648 | — |
| Mission Internal Medical Group | Mission Viejo | California | 92691 | — |
| Central Coast Cardiology | Salinas | California | 93901 | — |
| Alfieri Cardiology | Newark | Delaware | 19713 | — |
| St. Luke's Cardiology Associates | Jacksonville | Florida | 32216 | — |
| Cardiovascular Research Center of South Florida | Miami | Florida | 33173 | — |
| Research One | Orlando | Florida | 32806 | — |
| Cardiology Partners Clinical Research Institute | Wellington | Florida | 33449 | — |
| Fox Valley Clinical Research Center, LLC | Aurora | Illinois | 60504 | — |
| Research Integrity, LLC | Owensboro | Kentucky | 42303 | — |
| Louisiana Heart Center | Covington | Louisiana | 70403 | — |
| Louisiana Heart Center | Slidell | Louisiana | 70458 | — |
| Androscroggin Cardiology Associates DBA Maine Research Associates | Auburn | Maine | 04210 | — |
| Delmarva Heart Research Foundation, Inc | Salisbury | Maryland | 21804 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Cardiovascular Imaging Technologies | Kansas City | Missouri | 64111 | — |
| Dr. Michael Sacher | Massapequa | New York | 11758 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Heritage Cardiology | Camp Hill | Pennsylvania | 17011 | — |
| University of Pittsburgh Medical Center Cardiovascular Institute | Pittsburgh | Pennsylvania | 15213 | — |
| Kore Cardiovascular Research | Jackson | Tennessee | 38305 | — |
| East Texas Cardiology PA | Houston | Texas | 77002 | — |
| Mercury Medical, LLC | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01221272, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 3, 2014 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01221272 live on ClinicalTrials.gov.